The United States is a leader in the life sciences industry, but through deep regulatory reform, ambitious international strategy, and a surge of financings, China has recently enjoyed a biotechnology boom that in time could challenge this competitive edge.
Read MoreThe Massachusetts Biotechnology Council (MassBio®), launched an Academic-Industry Roundtable Series to create pathways for better collaboration and progress innovative technologies in the life sciences.
Read MoreEvery major life science conference we attend now has a digital health track, as this broad and evolving field and everything it encompasses continues to grab industry attention.
Read MoreWith the wrap up of the annual meeting of The American Society of Clinical Oncology (ASCO), we’re left with much to consider around new treatments in development that could deliver improved life expectancy and offer continued hope to millions of people.
Read MoreEuropean life science companies face a relative lack of capital compared to US companies. This gap engenders differing styles of investment and exit opportunities in Europe that can have meaningful implications for business plans and execution differences between the two continents.
Read MoreBack Bay is proud to sponsor the 9th Johns Hopkins Graduate Consulting Club Healthcare Case Competition, open to fellows at Johns Hopkins and other major universities around the world.
Read MoreThe underlying premise at Back Bay Life Science Advisors is that any accurate asset or company valuation must be derived from a fundamental understanding of the scientific, clinical, and commercial aspects of the financial models in use.
Read MoreWe’re proud to support academic innovation with our ongoing work around academic-industry partnering and through meaningful opportunities to bring together academic technology and commercial development.
Read MoreThis month, the FDA released Rare Diseases: Common Issues in Drug Development Guidance for Industry, which replaces the same 2015 document and includes ten sections with discussions ranging from scientific considerations in natural history and nonclinical studies, pathophysiology…
Read MoreAs we start a new year, we would like to share Back Bay’s latest thought piece, US Biosimilars: Opportunities and Challenges. Researched and written by Michelle Hoffmann, PhD and Jon Barry, MD, the insights are substantive, with calculated optimism.
Read More